Tags : aHUS

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria

Shots: Generium’s biosimilar of Eculizumab is developed using Selexis’ SUREtechnology Platform which is based on Selexis SGE (Selexis Genetic Elements) consist of human DNA based element, controlling the chromatin across mammalian cells Eculizumab is a monoclonal IgG2/4 Ab developed as a fifth biosimilar SUREtechnology Platform involved in reduction of the destruction of red blood cells […]Read More

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in

Shots: The P-III study involves assessing of Ultomiris (IV) in complement inhibitor-naïve patients with aHUS, receiving dose based on their weight varying upto 3,600 mg for 2 years P-III study results: reduction in thrombocytopenia in 83.9% patients; reduction in hemolysis in 76.8% patients; improved kidney function in 58.9% patients; No case of meningococcal infection observed; […]Read More